GlassScriptPhysician profile
James J Chamberlain
NPI 1093805681
$106,388.98
in general payments reported to CMS, 2019-2025
45 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $12K · 2021: $23K · 2022: $18K · 2023: $18K · 2024: $2,742 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,950 · Food and Beverage: $8,873 · Consulting Fee: $5,728 · Travel and Lodging: $5,033 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,956 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,950.00 |
| Food and Beverage | $8,873.40 |
| Consulting Fee | $5,727.50 |
| Travel and Lodging | $5,032.88 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,956.00 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35,062.22 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $22,378.65 | 2020-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $13,563.04 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $12,479.94 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $11,998.67 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $2,175.82 | 2019-2025 | |
| Medtronic, INC. | $1,775.22 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $1,569.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.94 | 2019-2025 | Jardiance, Synjardy |
| Insulet Corporation | $656.92 | 2019-2025 | Omnipod |
| Beta Bionics, INC. | $617.03 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $597.91 | 2019-2025 | Capvaxive |
| Ascensia Diabetes Care US INC. | $462.69 | 2023-2025 | |
| Corcept Therapeutics | $354.00 | 2020-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $222.68 | 2021-2025 | Gvoke Hypopen |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.